Slide 1: Cryoport, Inc. Second Quarter Earnings Call
Cryoport, Inc. Calendar Year 2017 Second Quarter Earnings Call NASDAQ: CYRX August 2017 1
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Highlights
Highlights Year-over-year revenue growth up 52% Impressive revenue growth driven by Selected by Novartis to support commercial launch of CTL019 robust pipeline Novartis plans filing in Q4 2017 in US and EU for JULIET approval Biopharma revenue up 69% year-over-year Growth in all markets Animal Healt
Slide 4: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Inflection point: Commercialization expected to begin in 2017 899 Ph. I: 284 (261 in 2016) Ph. II: 539 Novartis PDUFA date in September, Kite PDUFA date in November Clinical trials underway (475 in 2015) 3 additional BLAs for regenerative Q2 2017(a) Ph. II
Slide 5: Novartis Update
Novartis Update NASDAQ: CYRX August 2017 5
Slide 6: Additional Novartis Trials Supported
Additional Novartis Trials Supported NASDAQ: CYRX August 2017 6
Slide 7: Additional Q2 Biopharma Highlights
Additional Q2 Biopharma Highlights Kite completed BLA submission and has priority review for Axi-Cel Kite submitted MMA for European Medicines Agency approval. And on 8/7/17 Kite announced the first patient dosing of Axi-Cel in their European trial Alliance for Regenerative Medicine expects three mo
Slide 8: Revenue Trends
Revenue Trends Q2-2017 over Q2-2016 growth: +69% +15% +15% NASDAQ: CYRX August 2017 8
Slide 9: Clinical Trials Drive Revenue Growth
Clinical Trials Drive Revenue Growth 172 17 82 73 Potential Annual Revenue per Trial ($15-75K) ($75-150K) ($200K-1M) ($2M-20M) NASDAQ: CYRX August 2017 9
Slide 10: Revenue Trends 1H-2017
Revenue Trends 1H-2017 (six-month period ended June 30, 2017) Continuing double-digit growth in all markets fueled by biopharma - increased 82.3% for the 6-month period NASDAQ: CYRX August 2017 10
Slide 11: Financial Metrics Q2-2017
Financial Metrics Q2-2017 (quarter ended June 30, 2017) $1.5M 24M shares $12.9M Cash Debt free Accounts outstanding Receivable Biopharma Supporting 172 Total revenue Gross Margin revenue clinical trials, $2.9M 48% 17 Phase III up 52% up 8PP up 69% trials $0.08 net loss per share Growth in all market
Slide 12: Financial Summary
Financial Summary Statements of Operations Data: (in thousands) 2012 2013 2014 2015 2016 1H-2016 1H-2017 Net Revenues $ 863 $ 2,194 $ 3,572 $ 5,525 $ 7,679 $ 3,473 $ 5,630 Cost of revenues 1,761 2,052 2,630 3,847 4,577 2,109 2,983 Gross margin (loss) (898) 141 942 1,679 3,101 1,364 2,647 Loss from o
Slide 13: Summary
Summary Year-over-year quarterly revenue up 52% Impressive revenue growth driven by Animal Health and Reproductive Medicine markets up ~15% year-over-year robust pipeline Biopharma revenue up 69% year-over-year Selected for commercial support of CTL019 Novartis Novartis plans filing in Q4 2017 in US
Slide 14: Trusted by the Life Sciences Industry
1 4 Trusted by the Life Sciences Industry NASDAQ: CYRX August 2017 14
Slide 15: Science. Logistics. Certainty.
Science. Logistics. Certainty. NASDAQ: CYRX August 2017 15
Slide 16: Non-GAAP Financial Measures
Non-GAAP Financial Measures Note Regarding Use of Non-GAAP Financial Measures This news release contains non-GAAP financial measures as defined in Regulation G of the Securities Exchange Act of 1934. These financial measures are not calculated in accordance with generally accepted accounting princip